PMID- 28971301
OWN - NLM
STAT- MEDLINE
DCOM- 20190211
LR  - 20190215
IS  - 1931-7565 (Electronic)
IS  - 1931-7557 (Linking)
VI  - 12
IP  - 4
DP  - 2018 Aug
TI  - Distinctive pretreatment features of bilateral nucleus accumbens networks predict 
      early response to antidepressants in major depressive disorder.
PG  - 1042-1052
LID - 10.1007/s11682-017-9773-0 [doi]
AB  - The pretreatment neuroimaging markers from the resting-state brain network that 
      could predict the early response to antidepressants are still unclear. The aim of 
      the present study was to identify the performance of reward network features for 
      discriminating patients with a dampened response to antidepressants. A total of 
      81 major depressive disorder (MDD) patients (44 patients with 
      treatment-responsive depression (RD) and 37 patients with non-responding 
      depression (NRD)) and 43 healthy controls (HC) underwent resting-state functional 
      magnetic resonance imaging scans and clinical estimates. Bilateral nucleus 
      accumbens (NAcc)-based networks were constructed for further functional 
      connectivity (FC) analysis. The FC of the right superior frontal gyrus (SFG) 
      (area under curve (AUC) = 0.837) and left parahippocampus (AUC = 0.770) within 
      the left NAcc reward network, as well as the FC of the left SFG (AUC = 0.827) 
      within the right NAcc reward network, could distinguish NRD subjects from RD 
      subjects relatively well. Taken together, when considering the distinctive 
      connectional pattern of the bilateral reward circuits, the synthetical 
      differentiating effect was achieved to an optimal performance for discriminating 
      NRD patients (AUC = 0.869), with balanced sensitivity (0.838) and specificity 
      (0.818). The distinct pretreatment characteristics of the reward network make 
      specific contributions to the early response to antidepressants and establish a 
      promising imaging predictor for the classification of early efficacy.
FAU - Hou, Zhenghua
AU  - Hou Z
AD  - Department of Psychosomatics & Psychiatry, Institute of Psychosomatic Medicine, 
      Affiliated Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 
      210009, China.
FAU - Gong, Liang
AU  - Gong L
AD  - Department of Neurology, Institute of Neuropsychology, Affiliated Zhongda 
      Hospital, School of Medicine, Southeast University, Nanjing, 210009, China.
FAU - Zhi, Mengmeng
AU  - Zhi M
AD  - Department of Endocrinology, Zhongda Hospital, School of Medicine, Southeast 
      University, Nanjing, 210009, China.
FAU - Yin, Yingying
AU  - Yin Y
AD  - Department of Psychosomatics & Psychiatry, Institute of Psychosomatic Medicine, 
      Affiliated Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 
      210009, China.
FAU - Zhang, Yuqun
AU  - Zhang Y
AD  - Department of Psychosomatics & Psychiatry, Institute of Psychosomatic Medicine, 
      Affiliated Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 
      210009, China.
FAU - Xie, Chunming
AU  - Xie C
AD  - Department of Neurology, Institute of Neuropsychology, Affiliated Zhongda 
      Hospital, School of Medicine, Southeast University, Nanjing, 210009, China.
FAU - Yuan, Yonggui
AU  - Yuan Y
AD  - Department of Psychosomatics & Psychiatry, Institute of Psychosomatic Medicine, 
      Affiliated Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 
      210009, China. yygylh2000@sina.com.
LA  - eng
GR  - 81371488/National Natural Science Foundation of China/
GR  - 2016YFC1306702/National Key Research and Development Program of China/
GR  - 201706090193/the State Scholarship Fund of the China Scholarship Council/
GR  - 201706090199/the State Scholarship Fund of the China Scholarship Council/
GR  - YBJJ1742/the Scientific Research Foundation of the Graduate School of Southeast 
      University/
GR  - YBJJ1743/the Scientific Research Foundation of the Graduate School of Southeast 
      University/
PT  - Journal Article
PL  - United States
TA  - Brain Imaging Behav
JT  - Brain imaging and behavior
JID - 101300405
RN  - 0 (Antidepressive Agents)
SB  - IM
MH  - Antidepressive Agents/*therapeutic use
MH  - Brain Mapping
MH  - Depressive Disorder, Major/*diagnostic imaging/drug therapy/*physiopathology
MH  - Depressive Disorder, Treatment-Resistant/diagnostic imaging/drug 
      therapy/physiopathology
MH  - Female
MH  - Humans
MH  - *Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Neural Pathways/diagnostic imaging/physiopathology
MH  - Nucleus Accumbens/*diagnostic imaging/*physiopathology
MH  - Prognosis
MH  - Reward
MH  - Time Factors
OTO - NOTNLM
OT  - Antidepressant response
OT  - Depression
OT  - Imaging predictor
OT  - Nucleus accumbens
OT  - Reward network
EDAT- 2017/10/04 06:00
MHDA- 2019/02/12 06:00
CRDT- 2017/10/04 06:00
PHST- 2017/10/04 06:00 [pubmed]
PHST- 2019/02/12 06:00 [medline]
PHST- 2017/10/04 06:00 [entrez]
AID - 10.1007/s11682-017-9773-0 [pii]
AID - 10.1007/s11682-017-9773-0 [doi]
PST - ppublish
SO  - Brain Imaging Behav. 2018 Aug;12(4):1042-1052. doi: 10.1007/s11682-017-9773-0.